Home » Stocks » SDGR

Schrodinger, Inc. (SDGR)

Stock Price: $77.90 USD -0.46 (-0.59%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $77.85 -0.05 (-0.06%) Apr 16, 5:17 PM
Market Cap 5.45B
Revenue (ttm) 108.10M
Net Income (ttm) -24.46M
Shares Out 56.32M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $77.90
Previous Close $78.36
Change ($) -0.46
Change (%) -0.59%
Day's Open 78.30
Day's Range 76.35 - 78.56
Day's Volume 579,040
52-Week Range 40.12 - 117.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger presented new preclinical data from its CDC7 inhibitor program during AACR 21 Annual Virtual Meeting.

5 days ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that the company will participate in the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.

1 week ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger will host a webcast to review the preclinical data being presented at the AACR Annual Meeting.

2 weeks ago - Business Wire

These three companies have just one thing in common: the potential to offer a long-term windfall for stockholders.

Other stocks mentioned: OPEN, SKLZ
2 weeks ago - The Motley Fool

Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor.

3 weeks ago - The Motley Fool

NEW YORK--(BUSINESS WIRE)--Schrödinger will participate in the virtual Credit Suisse 2021 Healthcare Innovators Series on March 23, 2021.

1 month ago - Business Wire

This drug discovery company's stock just took a major hit.

1 month ago - The Motley Fool

NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger announced that preclinical data from its CDC7 program will be presented at the AACR Annual Meeting.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger today reported financial results for the fourth quarter and full year 2020.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will provide a corporate overview during the H.C. Wainwright Global Life Sciences Conference.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it has expanded its collaboration with Google Cloud.

1 month ago - Business Wire

Schrodinger is an exciting, next generation drug development and software player. However, at its core, it is a molecular modelling company, leading to vast opportunities. The TAM of the markets in whic...

2 months ago - Seeking Alpha

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...

Other stocks mentioned: MORF, OLMA
3 months ago - Invezz

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its ...

4 months ago - Business Wire

The company announced a partnership with Bristol Myers Squibb.

4 months ago - The Motley Fool

Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in milestone ...

Other stocks mentioned: BMY
4 months ago - Market Watch

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collabor...

Other stocks mentioned: BMY
4 months ago - Business Wire

Schrödinger stock is almost at half the price since peaking in the summer. Stock dilution hurt investors, but the market is betting on its software growth.

4 months ago - Seeking Alpha

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results fo...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the ...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a conference ...

5 months ago - Business Wire

Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual reality a...

Other stocks mentioned: CRWD, DDOG, GH, OKTA, U, ZS
5 months ago - CNN Business

Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Schrödinger, Inc. has exhibited a stock price slide since July, even as revenue growth continues above expectations.

7 months ago - Seeking Alpha

Three great performing yet relatively unknown med-tech stocks with a high upside.

Other stocks mentioned: SLP, VEEV
7 months ago - The Motley Fool

Schrödinger's computational platform integrates physics-based methods with machine-learning techniques to enable drug discovery and development of novel materials.

7 months ago - Seeking Alpha

Schrödinger has an innovative computational platform that accelerates the discovery of new molecules for use in therapeutics and industrial materials.

7 months ago - Seeking Alpha

Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based ...

8 months ago - PRNewsWire

A company that can speed up drug discovery; one that is already partnering with the world’s 20 biggest drug companies and appears to be just scratching the surface of its potential.

11 months ago - GuruFocus

Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Schrodinger - Taking Drug Discovery To The 'Space Age'

1 year ago - Seeking Alpha

The company continues to coast on a positive note from Citron Research.

1 year ago - The Motley Fool

1 hot IPO plus 1 comparison to Tesla equals 1/3 more stock value.

1 year ago - The Motley Fool

Notable activist short seller Andrew Left and his Citron Research firm said in a new report Schrodinger Inc (NASDAQ: SDGR) is the "most important IPO" in the past five years.

1 year ago - Benzinga

This IPO has been a success regardless.

1 year ago - The Motley Fool

About SDGR

Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharma... [Read more...]

Industry
Health Information Services
IPO Date
Feb 6, 2020
Stock Exchange
NASDAQ
Ticker Symbol
SDGR
Full Company Profile

Financial Performance

In 2020, Schrodinger's revenue was $108.10 million, an increase of 26.36% compared to the previous year's $85.54 million. Losses were -$24.46 million, -0.44% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 92.75, which is an increase of 19.06% from the latest price.

Price Target
$92.75
(19.06% upside)
Analyst Consensus: Buy